Phase II Study of 177Lu-DOTATATE for Progressive Metastatic Pheochromocytomas and Paragangliomas: Interim Analysis of Efficacy, Safety, and Biomarkers.

Journal:

Journal of Clinical Oncology

Published:

2025-08-20

DOI:

10.1200/jco-25-00791

Affiliations:

9

Authors:

20

Go to article

Institutions	Authors	Share
NIH National Cancer Institute (NCI), United States of America (USA)	11.000000 11.000000	0.55
NIH Clinical Center, United States of America (USA)	3.000000	0.15
NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), United States of America (USA)	2.500000	0.13
Uniformed Services University of the Health Sciences, United States of America (USA)	1.000000	0.05
NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), United States of America (USA)	1.000000	0.05
NIH NCI Center for Cancer Research (CCR), United States of America (USA)	1.000000	0.05
AKESO Holding, Czech Republic	0.500000	0.03

Interested in Biomedical Engineering?